Lenz Therapeutics, Inc. (LENZ) Stock Forecast Oct. 14, 2026
Analysis updated on Oct. 14, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Lenz Therapeutics, Inc. (LENZ) stock forecast summary
On Oct. 14, 2026, LENZ is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 4004 stocks scored that day.
Lenz Therapeutics, Inc. is a small-cap company with a market capitalization of $107M. It ranks number 60 by market capitalization among the 60 Biological Products, (No Diagnostic Substances) issuers in our coverage with a current forecast. Its P/B Ratio of 0.49x is the lowest of the 50 peers that report one.
A per-ticker accuracy statistic for LENZ is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.3%, buy ≥ +0.5%, sell < -0.6%, strong sell < -1.7% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-14 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, LENZ included.
Follow LENZ freeLENZ price chart and AI forecast
How LENZ ranks among 4004 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Lenz Therapeutics, Inc. (LENZ) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Biological Products, (No Diagnostic Substances) peers listed below that report each metric.
Valuation & Market
| Metric | LENZ | Rank |
|---|---|---|
| Market Cap | $107M | 60/60 |
| P/B Ratio | 0.49x | 50/50 |
| EPS | $-4.66 | – |
| Book Value/Share | $6.98 | – |
| Revenue/Share | $0.62 | – |
| FCF/Share | $-3.64 | – |
Profitability & Margins
| Metric | LENZ | Rank |
|---|---|---|
| ROE | -57.5% | 34/47 |
| ROA | -53.3% | 40/49 |
| ROIC | -61.8% | 41/50 |
| Operating Margin | -693.0% | 28/37 |
| Net Margin | -643.7% | 27/36 |
| EBT Margin | -645.4% | 29/38 |
| Tax Rate | -0.4% | – |
Financial Health
| Metric | LENZ | Rank |
|---|---|---|
| Current Ratio | 13.55x | 12/54 |
| Quick Ratio | 13.31x | 2/24 |
| D/E Ratio | 0.08x | 47/50 |
| Financial Leverage | 1.08x | 47/50 |
| Working Capital | $216M | 43/54 |
Cash Flow
| Metric | LENZ | Rank |
|---|---|---|
| Operating Cash Flow | -$114M | 26/52 |
| Free Cash Flow | -$114M | 23/45 |
| Capital Spending | -$510K | 6/45 |
| FCF/Sales | -584.5% | 25/30 |
| CapEx/Sales | 2.6% | 19/30 |
Operational Efficiency
| Metric | LENZ | Rank |
|---|---|---|
| Asset Turnover | 0.08x | 25/34 |
| Receivables Turnover | 44.3x | 2/22 |
| Fixed Assets Turnover | 19.5x | 7/34 |
| Days Sales Outstanding | 8 days | 21/22 |
Income Statement
| Metric | LENZ | Rank |
|---|---|---|
| Total Revenue | $19M | 28/34 |
| Operating Income | -$135M | 18/50 |
| Net Income | -$126M | 19/49 |
| R&D Expense | $4M | 51/51 |
| SG&A Expense | $152M | 18/22 |
Dividend & Shareholder Information
| Metric | LENZ | Rank |
|---|---|---|
| Shares Outstanding | 31M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $233M | 99.1% of assets |
| Cash & Short-term Investments | $24M | 10.3% of assets |
| Accounts Receivable | $440K | 0.2% of assets |
| Inventory | $4M | 1.8% of assets |
| Total Liabilities | $17M | 7.4% of assets |
| Short-term Debt | $11M | 4.5% of assets |
LENZ quarterly financials and insider trading
Lenz Therapeutics, Inc. (LENZ) industry peers
Companies classified under the same SEC industry code as Lenz Therapeutics, Inc. (Biological Products, (No Diagnostic Substances)): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| LENZ Lenz Therapeutics, Inc. | ▶ | $107M |
| AMGN Amgen Inc | ▼ | $223.19B |
| GILD Gilead Sciences, Inc. | ▶ | $183.41B |
| MRNA Moderna, Inc. | ▲ | $86.33B |
| ARGX Argenx Se | ▶ | $49.67B |
| RVMD Revolution Medicines, Inc. | ▲ | $40.39B |
| BIIB Biogen Inc. | ▼ | $33.79B |
| BNTX Biontech Se | ▶ | $22.51B |
| MESO Mesoblast Ltd | ▼ | $18.02B |
| EXEL Exelixis, Inc. | ▲ | $14.75B |
| NBIX Neurocrine Biosciences Inc | ▼ | $13.74B |
| HALO Halozyme Therapeutics, Inc. | ▲ | $12.44B |
| TECH Bio-Techne Corp | ▼ | $11.37B |
| IBRX Immunitybio, Inc. | ▲ | $10.39B |
| PCVX Vaxcyte, Inc. | ▲ | $9.94B |
| RGEN Repligen Corp | ▲ | $9.90B |
| QGEN Qiagen N.V. | ▼ | $9.86B |
| KRYS Krystal Biotech, Inc. | ▲ | $9.51B |
| TWST Twist Bioscience Corp | ▲ | $9.49B |
| KYMR Kymera Therapeutics, Inc. | ▲ | $8.87B |
| IOVA Iovance Biotherapeutics, Inc. | ▲ | $6.57B |
| IMVT Immunovant, Inc. | ▲ | $5.93B |
| KOD Kodiak Sciences Inc. | ▲ | $5.76B |
| CGON Cg Oncology, Inc. | ▲ | $5.53B |
| SRRK Scholar Rock Holding Corp | ▲ | $4.93B |
| CRSP Crispr Therapeutics Ag | ▲ | $4.84B |
| ADPT Adaptive Biotechnologies Corp | ▲ | $4.03B |
| RLAY Relay Therapeutics, Inc. | ▲ | $3.80B |
| TARS Tarsus Pharmaceuticals, Inc. | ▲ | $3.11B |
| DNLI Denali Therapeutics Inc. | ▲ | $2.94B |
| DBVT Dbv Technologies S.A. | ▼ | $2.67B |
| BEAM Beam Therapeutics Inc. | ▲ | $2.52B |
| ADMA Adma Biologics, Inc. | ▲ | $2.31B |
| NVAX Novavax Inc | ▲ | $2.11B |
| VCEL Vericel Corp | ▶ | $2.06B |
| BCRX Biocryst Pharmaceuticals Inc | ▲ | $2.06B |
| RXRX Recursion Pharmaceuticals, Inc. | ▲ | $2.05B |
| VIR Vir Biotechnology, Inc. | ▲ | $1.80B |
| SCNI Scinai Immunotherapeutics Ltd. | ▶ | $1.71B |
| ALVO Alvotech | ▶ | $1.68B |
| MAZE Maze Therapeutics, Inc. | ▲ | $1.48B |
| IMCR Immunocore Holdings Plc | ▲ | $1.43B |
| COAG Hemab Therapeutics Holdings, Inc. | ▲ | $1.39B |
| TSHA Taysha Gene Therapies, Inc. | ▲ | $1.17B |
| REPL Replimune Group, Inc. | ▲ | $1.14B |
| VOR Vor Biopharma Inc. | ▶ | $1.13B |
| JATT Zura Bio Ltd | ▼ | $1000M |
| VALN Valneva Se | ▼ | $965M |
| MGTX Meiragtx Holdings Plc | ▶ | $955M |
| IMTX Immatics N.V. | ▶ | $916M |
| CGEM Cullinan Therapeutics, Inc. | ▲ | $907M |
| GLUE Monte Rosa Therapeutics, Inc. | ▲ | $844M |
| ODTX Odyssey Therapeutics, Inc. | ▲ | $829M |
| DNA Ginkgo Bioworks Holdings, Inc. | ▲ | $792M |
| SANA Sana Biotechnology, Inc. | ▶ | $721M |
| CADL Candel Therapeutics, Inc. | ▲ | $709M |
| FDMT 4d Molecular Therapeutics, Inc. | ▲ | $682M |
| AURA Aura Biosciences, Inc. | ▲ | $650M |
| SLDB Solid Biosciences Inc. | ▲ | $624M |
| PRME Prime Medicine, Inc. | ▲ | $602M |
Where LENZ sits on the market map
Lenz Therapeutics, Inc. (LENZ) stock news
Loading...
Lenz Therapeutics, Inc. (LENZ) stock forecast FAQ
What is the Lenz Therapeutics, Inc. (LENZ) stock forecast?
On Oct. 14, 2026, LENZ is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 4004 stocks scored that day.
How accurate are Lenz Therapeutics, Inc. stock predictions?
A per-ticker accuracy statistic for LENZ is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Lenz Therapeutics, Inc. forecasts updated?
Lenz Therapeutics, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 14, 2026.
Which companies are Lenz Therapeutics, Inc.'s industry peers?
60 issuers in our coverage, LENZ included, share the SEC industry code Biological Products, (No Diagnostic Substances). The largest are: Amgen Inc (AMGN), Gilead Sciences, Inc. (GILD), Moderna, Inc. (MRNA), Argenx Se (ARGX), Revolution Medicines, Inc. (RVMD), Biogen Inc. (BIIB).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.